16 April 2024 Ex-head of Kramer Levin life sciences practice leaves for new firm | 20 years of experience includes numerous multi-billion dollar cases for some of the world’s best-selling drugs.
16 April 2024
11 April 2024
Latest Features
Plant Varieties
Applicants face tough scrutiny for claims around the laws of nature, but details of new processes, steps or guidance can help patents pass the courts’ two-step test, says Michael Taylor of Harness IP.
Biotechnology
It is critical that the emerging field of personalised medicine receives appropriate patent protection, explain Joel Coles and Theo Cooper of Powell Gilbert.
Unified Patent Court
Well-resourced NPEs looking to play the injunction card are eyeing up the court—companies with European operations should prepare, say Tom Oliver and Jessica Rosethorn of Powell Gilbert.
Biotechnology
Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs.
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.
Generics
While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
Biotechnology
Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper.
More News
4 April 2024 The Federal Circuit upholds a ruling in favour of Microsoft against an Orlando tech company | Dispute concerned 3D medical imaging technology | Court affirms PTAB’s decision to invalidate most of the patent.
4 April 2024 Senior pharma attorney and LSPN Boston speaker delves into emerging tech and patent law, the importance of communication and awareness, and the challenge of enablement | Advice on effective management of IP portfolios in the life sciences sector.
2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.
2 April 2024 Former Biogen counsel brings expertise in patent litigation for startups- Fortune 500 biotech giants | Experience in gene sequencing, computational biology, diagnostic software, and biosimilars.
28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.
28 March 2024 Roche patent attorney Matt Flinders shares his perspectives on the impact of emerging tech on patent law and strategy | Insights into the challenges companies are facing with emerging tech.
26 March 2024 ERS Genomics, founded by CRISPR co-inventor Emmanuelle Charpentier, celebrates as China rejects invalidity challenges | News follows on heels of a similar Japan Patent Office decision.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox